Deal overview
| Target | ALEXION PHARMACEUTICALS INC |
|---|---|
| Bidder | ASTRAZENECA PLC |
| Price | £0.00 Full version or £25.00 Light version |
| Publication Date | Dec 12, 2020 |
| Abstract | On Saturday 12 December 2020, AstraZeneca plc ("AstraZeneca"), a UK-headquartered pharmaceuticals company, announced a recommended mixed cash and shares offer for the US-listed company Alexion Pharmaceuticals Inc ("Alexion"). The offer terms valued each Alexion share at $175.29 and 100% of Alexion's share capital at $39 billion. Alexion shareholders would own circa 15% of the ... |
| Number of pages (Full version) | 0 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2024 M&A Monitor Limited
